On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.

The Wilson Sonsini team that advised Nervonik includes:

Corporate
Scott Murano
Roy Argand
Davelyn Couch Bulovas
Riven (Yili) Bu
Jackie Ito
Esther Lim
Tim Ingram
Tamra Mast

Delaware Corporate
Ryan Greecher

Technology Transactions
Shefali Lumb
Kimberly Parry
Alex Key

For more information, please see Nervonik’s news release.